Boston Scientific announced positive data from the HI-PEITHO global randomized trial of the EKOS Endovascular System in intermediate-risk pulmonary embolism. The results suggest clinical benefit that could support wider adoption and potential regulatory/label expansion, improving device revenue prospects. This is modestly positive for BSX and could move the stock by low-single-digit percentages.
Boston Scientific announced positive data from the HI-PEITHO global randomized trial of the EKOS Endovascular System in intermediate-risk pulmonary embolism. The results suggest clinical benefit that could support wider adoption and potential regulatory/label expansion, improving device revenue prospects. This is modestly positive for BSX and could move the stock by low-single-digit percentages.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
